Management of CLL Patients with Elevated White Blood Cell Counts

Assessment and Management Principles

The National Comprehensive Cancer Network recommends evaluating CLL patients with WBC of 150,000/μL for symptoms of leukostasis, evidence of progressive marrow failure, massive or symptomatic splenomegaly, massive or symptomatic lymphadenopathy, progressive lymphocytosis, and constitutional symptoms 1, 2
The American Society of Clinical Oncology guidelines state that high WBC count alone is not an indication for treatment, and the absolute lymphocyte count should not be used as the sole indicator for treatment 1, 3
Leukostasis is rare in CLL, and symptoms associated with leukocyte aggregates rarely occur in CLL patients, even with markedly elevated counts 1, 3
The National Comprehensive Cancer Network guidelines recommend that immediate treatment is typically only needed if WBC >200-300 × 10^9/L AND symptoms of leukostasis are present 3, 4

For asymptomatic CLL patients with no criteria for active disease, the European Society for Medical Oncology recommends continuing observation with regular monitoring 1, 2, 5
For patients with other criteria for active disease, the National Comprehensive Cancer Network guidelines recommend initiating appropriate CLL-directed therapy based on patient characteristics and molecular profile 2, 5, 6
For patients with del(17p) or TP53 mutations, the National Comprehensive Cancer Network guidelines recommend BTK inhibitors or venetoclax-based regimens 6
For patients without del(17p) or TP53 mutations, the European Society for Medical Oncology recommends considering age, comorbidities, and IGHV mutation status to guide therapy selection 2, 6

The International Workshop on Chronic Lymphocytic Leukemia notes that assessing for del(17p), TP53 mutations, and IGHV status is crucial before initiating treatment, as these guide therapy selection 2, 5
The National Comprehensive Cancer Network guidelines explicitly discourage initiating treatment based solely on WBC count 1, 3